Skip to main content
. 2017 Aug 3;2(15):e91588. doi: 10.1172/jci.insight.91588

Figure 7. Inhibition of ERK1/2 activation suppresses Smad2 activation in both nonmyocyte and myocyte compartments.

Figure 7

Representative coimmunostaining of (A) pSmad2 (red, row 1) and vimentin (pink, row 2) and of (B) pERK1/2 (red, row 1) and vimentin (pink, row 2) of myocyte-enriched sections of Fbn1C1039G/+ hearts subjected to sham vs. TAC, with treatment groups. Scale bars: 20 μm; zoom inset: ×2 of nonmyocyte-enriched areas. Blue, DAPI (nuclei); green, lipofuscin (myocytes).